Literature DB >> 14689577

Ras signaling in prostate cancer progression.

Michael J Weber1, Daniel Gioeli.   

Abstract

When prostate cancer is first detected it generally is dependent on the presence of androgens for growth, and responds to androgen ablation therapies. However, the disease often recurs in a disseminated and apparently androgen independent (AI) form, and in this state is almost invariably fatal. Considerable evidence indicates that the Androgen receptor (AR) continues to be required even in androgen independent (AI) disease. Thus, a key to understanding hormone independent prostate cancer is to determine the mechanism(s) by which the AR can function even in the absence of physiologic levels of androgen. In this article, we argue that growth factors and receptors that utilize Ras family members drive prostate cancer progression to a state of androgen hypersensitivity; and that post-translational modifications (e.g., phosphorylations) of transcriptional cofactors might be responsible for modulating the function of the AR so that it is active even at low concentrations of androgen. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14689577     DOI: 10.1002/jcb.10683

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  61 in total

1.  Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases.

Authors:  Ferenc G Rick; Andrew V Schally; Luca Szalontay; Norman L Block; Karoly Szepeshazi; Mehrdad Nadji; Marta Zarandi; Florian Hohla; Stefan Buchholz; Stephan Seitz
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-18       Impact factor: 11.205

2.  RasGRP3 contributes to formation and maintenance of the prostate cancer phenotype.

Authors:  Dazhi Yang; Noemi Kedei; Luowei Li; Juan Tao; Julia F Velasquez; Aleksandra M Michalowski; Balázs I Tóth; Rita Marincsák; Attila Varga; Tamás Bíró; Stuart H Yuspa; Peter M Blumberg
Journal:  Cancer Res       Date:  2010-09-28       Impact factor: 12.701

3.  Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells.

Authors:  Peter C Hollenhorst; Mary W Ferris; Megan A Hull; Heejoon Chae; Sun Kim; Barbara J Graves
Journal:  Genes Dev       Date:  2011-10-15       Impact factor: 11.361

4.  Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.

Authors:  James A McCubrey; Melissa L Sokolosky; Brian D Lehmann; Jackson R Taylor; Patrick M Navolanic; William H Chappell; Stephen L Abrams; Kristin M Stadelman; Ellis W T Wong; Negin Misaghian; Stefan Horn; Jörg Bäsecke; Massimo Libra; Franca Stivala; Giovanni Ligresti; Agostino Tafuri; Michele Milella; Marek Zarzycki; Andrzej Dzugaj; Francesca Chiarini; Camilla Evangelisti; Alberto M Martelli; David M Terrian; Richard A Franklin; Linda S Steelman
Journal:  Adv Enzyme Regul       Date:  2008-02-21

5.  GPRC6A regulates prostate cancer progression.

Authors:  Min Pi; L Darryl Quarles
Journal:  Prostate       Date:  2011-06-16       Impact factor: 4.104

6.  Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic.

Authors:  Ntube N O Ngalame; Erik J Tokar; Rachel J Person; Yuanyuan Xu; Michael P Waalkes
Journal:  Toxicol Sci       Date:  2014-01-15       Impact factor: 4.849

7.  Selective amino acid restriction differentially affects the motility and directionality of DU145 and PC3 prostate cancer cells.

Authors:  Ya-Min Fu; Zu-Xi Yu; Huimin Lin; Xing Fu; Gary G Meadows
Journal:  J Cell Physiol       Date:  2008-10       Impact factor: 6.384

8.  Integrin signaling aberrations in prostate cancer.

Authors:  Hira Lal Goel; Naved Alam; Isaac N S Johnson; Lucia R Languino
Journal:  Am J Transl Res       Date:  2009-04-20       Impact factor: 4.060

9.  ERK and AKT signaling drive MED1 overexpression in prostate cancer in association with elevated proliferation and tumorigenicity.

Authors:  Feng Jin; Shazia Irshad; Wei Yu; Madesh Belakavadi; Marina Chekmareva; Michael M Ittmann; Cory Abate-Shen; Joseph D Fondell
Journal:  Mol Cancer Res       Date:  2013-03-28       Impact factor: 5.852

10.  Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes.

Authors:  Faris Farassati; Weihong Pan; Farnaz Yamoutpour; Susann Henke; Mark Piedra; Silke Frahm; Said Al-Tawil; Wells I Mangrum; Luis F Parada; Samuel D Rabkin; Robert L Martuza; Andreas Kurtz
Journal:  Am J Pathol       Date:  2008-11-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.